9H4 Stock Overview
A diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
LungLife AI, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.099 |
| 52 Week High | UK£0.94 |
| 52 Week Low | UK£0.087 |
| Beta | -0.15 |
| 11 Month Change | -5.71% |
| 3 Month Change | -30.77% |
| 1 Year Change | -88.88% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9H4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.8% | -0.7% | -0.02% |
| 1Y | -88.9% | -17.2% | 8.2% |
Return vs Industry: 9H4 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 9H4 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 9H4 volatility | |
|---|---|
| 9H4 Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9H4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9H4's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 8 | Paul Pagano | lunglifeai.com |
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019.
LungLife AI, Inc. Fundamentals Summary
| 9H4 fundamental statistics | |
|---|---|
| Market cap | €3.32m |
| Earnings (TTM) | -€4.29m |
| Revenue (TTM) | €27.85k |
119.2x
P/S Ratio-0.8x
P/E RatioIs 9H4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9H4 income statement (TTM) | |
|---|---|
| Revenue | US$29.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$29.00k |
| Other Expenses | US$4.50m |
| Earnings | -US$4.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 100.00% |
| Net Profit Margin | -15,403.45% |
| Debt/Equity Ratio | 0% |
How did 9H4 perform over the long term?
See historical performance and comparison